GlassScriptPhysician profile
Carole Tong
NPI 1811472749
$3,471.48
in general payments reported to CMS, 2019-2025
10 companies · $265 in 2025
The $265 reported for 2025 was more than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $81.38 · 2021: $92.37 · 2022: $1,891 · 2023: $1,025 · 2024: $117 · 2025: $265.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,046 · Travel and Lodging: $241 · Education: $99.99 · Consulting Fee: $20.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,045.74 |
| Travel and Lodging | $241.45 |
| Education | $99.99 |
| Consulting Fee | $20.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Vision Care, INC. | $1,737.88 | 2019-2025 | Acuvue |
| Alcon Vision LLC | $1,078.18 | 2021-2025 | Air Optix, Dailies Total1, Dailies Total1 Multifocal |
| Coopervision INC. | $305.36 | 2022-2025 | Misight Contact Lens, Myday Contact Lens |
| Mallinckrodt Hospital Products INC. | $137.75 | 2025 | Acthar |
| Regeneron Healthcare Solutions, INC. | $97.50 | 2022 | |
| Biotissue Holdings INC. | $36.38 | 2021 | |
| Astellas Pharma US INC | $30.06 | 2024 | Izervay |
| Bausch & Lomb Americas INC. | $17.89 | 2024 | Infuse |
| The Walman Optical Company | $16.08 | 2022 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $14.40 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carole Tong listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.